ASH 2024 | Ponatinib versus imatinib monotherapy after combination with chemotherapy in newly diagnosed Ph+ ALL
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the findings of a post-hoc subgroup analysis of the Phase III PhALLCON study (NCT03589326). This analysis highlighted that patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with ponatinib monotherapy after combination with chemotherapy had a significantly higher likelihood of continuing with long-term maintenance compared to those patients receiving imatinib. This suggests that ponatinib’s efficacy extends beyond short-term benefits, potentially making it a more effective first-line treatment than imatinib when administered as monotherapy following combination with attenuated chemotherapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This abstract is a sub-study of the PhALLCON study and really what it studies is what occurs in long-term patients who receive the ponatinib arm and the imatinib arm when the chemotherapy part is finished and how the patients remained in each of the two arms of the study. And it was demonstrated that more patients continued in the ponatinib arm for a long time for a maintenance phase and really it was significantly higher than that occurred in the imatinib arm...
This abstract is a sub-study of the PhALLCON study and really what it studies is what occurs in long-term patients who receive the ponatinib arm and the imatinib arm when the chemotherapy part is finished and how the patients remained in each of the two arms of the study. And it was demonstrated that more patients continued in the ponatinib arm for a long time for a maintenance phase and really it was significantly higher than that occurred in the imatinib arm. This implies that there were long-term patients, more long-term patients, under TKI in the experimental arm of ponatinib. And this is an indirect evidence that the ponatinib is active not only a short time, but also a long time, or in this case, better than what occurs with imatinib. So this is an indirect evidence that ponatinib is more efficacious as first line than imatinib when both were combined with attenuated chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
